اخبار و اعلانات

 آمار

تعداد نشریات283
تعداد نشریات سازمان81
تعداد شماره‌ها2,722
تعداد مقالات31,007
تعداد مشاهده مقاله27,071,770
تعداد دریافت فایل اصل مقاله16,156,313
Ghalib Farhood, R, Abd Ali Al-Humairi, I. (1400). Immunohistochemical study of Ki-67 in Hyperplastic and Endometrium Carcinoma: A Comparative Study. سامانه مدیریت نشریات علمی, 77(1), 229-234. doi: 10.22092/ari.2021.356540.1865
R Ghalib Farhood; I Abd Ali Al-Humairi. "Immunohistochemical study of Ki-67 in Hyperplastic and Endometrium Carcinoma: A Comparative Study". سامانه مدیریت نشریات علمی, 77, 1, 1400, 229-234. doi: 10.22092/ari.2021.356540.1865
Ghalib Farhood, R, Abd Ali Al-Humairi, I. (1400). 'Immunohistochemical study of Ki-67 in Hyperplastic and Endometrium Carcinoma: A Comparative Study', سامانه مدیریت نشریات علمی, 77(1), pp. 229-234. doi: 10.22092/ari.2021.356540.1865
Ghalib Farhood, R, Abd Ali Al-Humairi, I. Immunohistochemical study of Ki-67 in Hyperplastic and Endometrium Carcinoma: A Comparative Study. سامانه مدیریت نشریات علمی, 1400; 77(1): 229-234. doi: 10.22092/ari.2021.356540.1865

Immunohistochemical study of Ki-67 in Hyperplastic and Endometrium Carcinoma: A Comparative Study

Archives of Razi Institute
مقاله 31، دوره 77، شماره 1، فروردین و اردیبهشت 2022، صفحه 229-234    اصل مقاله (757.74 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2021.356540.1865
نویسندگان
R Ghalib Farhood* 1؛ I Abd Ali Al-Humairi2
1Department of Pathology, College of Medicine, University of Babylon, Babylon, Iraq
2Department of Pathology, Hammurabi College of Medicine, University of Babylon, Babylon, Iraq
چکیده
Endometrial hyperplasia is defined as a common clinical disorder caused by the increased levels of estrogens with low levels of progesterone; therefore, this hormonal imbalance leads to an increase in the proliferation rate of the endometrial cells. Endometrial carcinoma is one of the most important malignancies affecting women all over the world "accounting for 37.7% of all other disorders affecting the female reproductive system". The expression of the Ki-67 protein is related to the proliferative behavior of malignant tumor cell populations of their own, allowing it to be used as a marker of tumor aggressiveness. The present study was conducted to examine the expression of the proliferation marker, Ki-67 in various endometrial lesions. Ki-67 expression was evaluated in 60 endometrial samples that resulted as either endometrial curetting or hysterectomy specimens, diagnosed with simple hyperplasia (n=10), complex hyperplasia (n=20), atypical hyperplasia (n=6), and endometrial carcinoma (n=24). In patients with endometrial carcinoma, there was an increased expression of Ki-67, compared to proliferative endometrium and simple hyperplasia (P-value=0.0001). There was no such discrepancy between atypical hyperplasia and endometrial carcinoma cases. The expression of Ki-67 showed a positive association with the degree of endometrial cancer (P-value=0.0013), however, not with the age of the patients (P-value>0.05). There is a wide range of variations in the proliferation rate within the development of different endometrial lesions, including benign and malignant lesions. Our findings may be of value in differential diagnosis and prognosis of endometrial hyperplasia and endometrial carcinoma.
کلیدواژه‌ها
Endometrial lesions؛ Ki-67؛ Manual IHC
سایر فایل های مرتبط با مقاله
مراجع
  1. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long‐term study of “untreated” hyperplasia in 170 patients. Cancer. 1985;56(2):403-12.
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. Cancer J Clin. 2016;66(1):7-30.
  3. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer. 2008.
  4. Gabryś M. Epidemiologia i etiopatogeneza raka błony śluzowej trzonu macicy. Ginekologia onkologiczna Urban & Partner, Wrocław. 2006:683-94.
  5. Ogane N, Yasuda M, Kato H, Kato T, Yano M, Kameda Y, et al. Cleaved caspase‐3 expression is a potential prognostic factor for endometrial cancer with positive peritoneal cytology. Cytopathology. 2018;29(3):254-61.
  6. Bullwinkel J, Baron‐Lühr B, Lüdemann A, Wohlenberg C, Gerdes J, Scholzen T. Ki‐67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol. 2006;206(3):624-35.
  7. Cuylen S, Blaukopf C, Politi AZ, Müller-Reichert T, Neumann B, Poser I, et al. Ki-67 acts as a biological surfactant to disperse mitotic chromosomes. Nature. 2016;535(7611):308-12.
  8. Darzynkiewicz Z, Zhao H, Zhang S, Marietta YL, Ernest YL, Zhang Z. Initiation and termination of DNA replication during S phase in relation to cyclins D1, E and A, p21WAF1, Cdt1 and the p12 subunit of DNA polymerase δ revealed in individual cells by cytometry. Oncotarget. 2015;6(14):11735.
  9. Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004;1014(1):13-27.
  10. Le Guellec S, Perallon R, Alunni J-P, Charitansky H, Leaha C, Gonzalez AM, et al., editors. Neoadjuvant treatment of breast cancer: implications for the pathologist. Ann Pathol; 2011.
  11. Li LT, Jiang G, Chen Q, Zheng JN. Ki67 is a promising molecular target in the diagnosis of cancer. Mol Med Rep. 2015;11(3):1566-72.
  12. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11(2):174-83.
  13. Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. JNatl Cancer Inst. 2011;103(22):1656-64.
  14. Goldhirsch A, Ingle JN, Gelber R, Coates A, Thürlimann B, Senn H-J. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20(8):1319-29.
  15. Gurda GT, Baras AS, Kurman RJ. Ki-67 index as an ancillary tool in the differential diagnosis of proliferative endometrial lesions with secretory change. Int J Gynecol Pathol. 2014;33(2):114-9.
  16. Zhong W, Peng J, Wu D, Han Z, Bi X, Dai Q. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clin Invest Med. 2008:8-15.
  17. Shevra C, Ghosh A, Kumar M. Cyclin D1 and Ki-67 expression in normal, hyperplastic and neoplastic endometrium. J Postgrad Med. 2015;61(1):15.
  18. Huvila J, Talve L, Carpén O, Edqvist P-H, Pontén F, Grénman S, et al. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. Gynecol Oncol. 2013;130(3):463-9.
  19. Liu T, Gao H, Yang M, Zhao T, Liu Y, Lou G. Correlation of TNFAIP8 overexpression with the proliferation, metastasis, and disease-free survival in endometrial cancer. Tumor Biol. 2014;35(6):5805-14.
  20. Stefansson I, Salvesen H, Immervoll H, Akslen L. Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology. 2004;44(5):472-9.
  21. Kitson S, Sivalingam VN, Bolton J, McVey R, Nickkho-Amiry M, Powell ME, et al. Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies. Mod Pathol. 2017;30(3):459-68.
22.          Truskinovsky AM, Lifschitz-Mercer B, Czernobilsky B. Hyperplasia and carcinoma in secretory endometrium: a diagnostic challenge. Int J Gynecol Pathol. 2014;33(2):107-13. 

آمار
تعداد مشاهده مقاله: 1,872
تعداد دریافت فایل اصل مقاله: 401


counter
سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب